The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Final OS findings of zolbetuximab and FOLFOX6 in the SPOTLIGHT trial
Kohei Shitara, MD, National Cancer Center Hospital East, Tokyo, Japan, discusses the final overall survival (OS) analysis of the Phase III SPOTLIGHT study (NCT03504397) of zolbetuximab combined with modified FOLFOX6 (mFOLFOX6) in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. Results showed significant improvements in progression-free survival (PFS) and OS with zolbetuximab. Safety and tolerability were consistent with no new findings, affirming zolbetuximab and mFOLFOX6 as a potential new standard of care in this space. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role – ALX Oncology; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Guardant Health; MSD; Novartis; Ono Pharmaceutical; Takeda; Zymeworks
Research Funding – Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)
